| In millions, except per share items | Sep-30-18 | Jun-30-18 | Mar-31-18 | Dec-31-17 | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Cash flows used in operating activities: | | | | | | | | |
| Net loss | -21.3 | -13.5 | -18.6 | -32.4 | 6.4 | -21.6 | -29.5 | -86.1 |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Depreciation | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Amortization of intangibles | 2.3 | 1.4 | 9.8 | | 18.2 | 18.2 | 18.5 | |
| Amortization of deferred financing costs | 0.9 | 1.0 | 1.0 | 0.9 | 0.9 | 0.9 | 0.6 | 0.6 |
| Accretion expense | 2.3 | 2.2 | 2.2 | 2.4 | 2.0 | 2.2 | 2.0 | 2.0 |
| PIK Interest | 0.4 | 0.5 | 0.5 | | | | | |
| Amortization of acquisition related inventory step-up | 2.2 | | | | | | | |
| Stock compensation expense | 0.4 | 0.5 | 0.4 | 0.6 | 0.5 | 0.7 | 0.7 | 0.6 |
| Unrealized foreign currency loss | 0.7 | | | | | | | |
| Fair market value change in contingent consideration | | -0.1 | 0.3 | -1.4 | 0.9 | -0.9 | 0.3 | -2.7 |
| Fair market value change in derivative liability | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.3 | 0.4 | -2.2 |
| Gain from legal settlement | | | | | -10.5 | | | |
| Gain from exchange of debt | -0.1 | | | | -14.7 | | | |
| Impairment of fixed assets | 0.1 | | | 18.5 | 0.0 | | | 53.8 |
| Gain on sale of assets | | -0.4 | | | | | | |
| (Increase) decrease in operating assets, net of effects of acquisitions: | | | | | | | | |
| Accounts receivable | -3.6 | 1.7 | 8.3 | 3.1 | -3.1 | -14.2 | 19.7 | -6.0 |
| Income tax receivable | 0.1 | 0.0 | 0.1 | 0.3 | 0.0 | 0.2 | 0.7 | 1.9 |
| Inventory | 3.2 | 0.3 | 0.0 | 2.7 | 0.4 | -1.0 | 0.3 | 0.5 |
| Prepaid expenses and other assets | -6.1 | 1.2 | 1.3 | -2.8 | -7.5 | 1.6 | -0.7 | -1.2 |
| Increase (decrease) in operating liabilities, net of effects of acquisitions: | | | | | | | | |
| Accounts payable and accrued expenses | 1.4 | 0.2 | -1.9 | 0.9 | -3.9 | 2.7 | -1.8 | -1.0 |
| Accrued allowances | 4.7 | -6.2 | 3.9 | -1.9 | 2.5 | -0.1 | -5.2 | 4.6 |
| Interest payable | -3.5 | 4.4 | -4.9 | 4.5 | -4.4 | 4.0 | -4.6 | 4.3 |
| Other liabilities | -0.7 | 0.0 | -1.7 | -0.4 | -0.2 | 0.2 | -1.9 | -0.3 |
| Net cash used in operating activities | -17.3 | -7.8 | -0.3 | 3.3 | 0.0 | -8.4 | -0.8 | 6.4 |
| Cash flows from investing activities: | | | | | | | | |
| Acquisition of Orexigen, net of cash acquired | -69.2 | | | | | | | -0.6 |
| Proceeds from sale of non-core assets | | 0.4 | | | | | | |
| Purchase of software and equipment | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | | 0.0 | 0.0 |
| Net cash used in investing activities | -69.3 | 0.4 | 0.0 | 2.0 | 0.0 | | 0.0 | 0.0 |
| |
| Cash flows from financing activities: | | | | | | | | |
| Proceeds from issuance of convertible notes | | | | | | | | |
| Tax benefit on stock-based awards | | | | | | | | |
| Proceeds from exercise of stock options | | | | | | | | |
| Nalpropion - Capital Contribution | 41.3 | | | | | | | |
| Proceeds from 2018 Term Loan | 41.3 | | | | | | | |
| Net proceeds from Delayed Draw Term Loan | 9.2 | | | | 30.0 | | | |
| Payments on Treximet Secured Notes | | | -5.4 | | -4.7 | | -12.8 | |
| Payment on financing costs | | | -0.2 | 0.0 | -13.6 | | | |
| Net payments on credit facilities | | | | | 0.2 | | | |
| Payments on mortgages and capital leases | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Proceeds from issuance of common stock, net of tax and costs | | 0.5 | | | 1.1 | | | |
| Shares withheld for the payment of taxes | 0.0 | 0.0 | | 0.0 | -0.1 | | | 0.0 |
| Stock issuance costs | -0.5 | | | | | | | |
| Net cash provided by financing activities | 91.1 | 0.4 | -5.6 | 0.3 | 12.9 | 0.0 | -12.8 | 1.5 |
| Effect of exchange rate changes on cash and cash equivalents | 0.1 | | | | | | | |
| Net decrease in cash and cash equivalents | 4.6 | -7.0 | -5.9 | 5.6 | 12.9 | -8.4 | -13.6 | 7.9 |
| Cash and cash equivalents, beginning of period | | | 32.8 | | | | 36.4 | |
| Cash and cash equivalents, end of period | 4.6 | -7.0 | 26.9 | 5.6 | 12.9 | -8.4 | 22.7 | 7.9 |